Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel targeted therapies known as Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. The company was founded in 2000 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.

NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will present at the Cantor Fitzgerald Virtual Global Healthcare Conference, which is being held from September 27 th to 30th.

Actinium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29th

NEW YORK, Sept. 27, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple updates on its R&D capabilities.

Actinium Announces Expansion of R&D Team and Facilities to Accelerate Research Programs Focused on Solid Tumors and Novel Combinations with Checkpoint Inhibitors and Radioconjugates

NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple senior leadership appointments including Arun Swaminathan, Ph.D.

Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and Commercial Officer, New Chief Medical Officer and Vice President, Patent and Legal Counsel

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will present at four upcoming investor conferences.

Actinium to Present at Four Upcoming Investor Conferences

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it has completed enrollment of the pivotal Phase 3 SIERRA trial for Iomab-B, an Antibody Radiation Conjugate (ARC) comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131.

Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B

Actinium has taken years to bring its therapy to (near) the market. However, there are no serious challenges to the data we have seen so far.

Actinium: A Story Of Delays And Promises, About To Come To Fruition

NEW YORK, June 28, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced today that it will be added to the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, according to a preliminary list of additions posted June 4, 2021. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.

Actinium Pharmaceuticals Announces Inclusion in Russell Microcap® Index

NEW YORK, June 17, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its intellectual property portfolio around its lead Phase 3 candidate, Iomab-B, has been further strengthened internationally. In the EU, Actinium has been issued a patent covering the composition and methods administration of Iomab-B, an Antibody Radiation Conjugate (ARC) comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131.

Actinium Further Strengthens Patent Portfolio with International IP Covering the Composition and Methods of Administration of Iomab-B Antibody Radiation Conjugate in the EU and Japan

Actinium Pharmaceuticals Inc (NYSE: ATNM) highlighted data from its pivotal Phase 3 SIERRA trial evaluating Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (AML) aged 55 years and above. Iomab-B radiotherapy is intended to be a targeted conditioning (preparing) agent to enable a potentially curative bone marrow transplant (BMT).

Actinium's Targeted Radiotherapy Achieves 100% Bone Marrow Transplant Engraftment

NEW YORK, June 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted data from its pivotal Phase 3 SIERRA trial for Iomab-B in an oral presentation at the 2021 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, which is being held virtually from June 11 th – 14th. Iomab-B is radiotherapy that targets cells expressing CD45, a protein found only on blood cancer cells and immune cells including bone marrow stem cells, with the radioisotope iodine-131 and is intended to be a targeted conditioning agent to enable potentially curative bone marrow transplant (BMT).

Pivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment in Patients Treated with Iomab-B presented at the 2021 Virtual SNMMI Conference

NEW YORK, June 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium") today highlighted safety data from its ongoing pivotal Phase 3 SIERRA trial of Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (r/r AML) were presented at the 2021 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held virtually July 11 th – 14th. The presentation highlighted Iomab-B's targeting ability and corresponding safety data from 113 patients, representing 75% of patient enrollment on the SIERRA trial.

Safety Data Highlighting Low Rates of Adverse Events and Non-Relapse Transplant Related Mortality in Patients Receiving Iomab-B Presented at 2021 SNMMI Virtual Conference

Actinium (ATNM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Surging Earnings Estimates Signal Good News for Actinium (ATNM)

Actinium Pharmaceuticals Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company, is developing antibody radiation-conjugates (ARCs) to combine the targeting ability of antibodies with the cell-killing ability of radiation. The Company is a leader in the targeted radiotherapy field for cancer patients who can't tolerate chemotherapy and radiation.

Actinium Activates Radiation Inside the Body for Target Conditioning of Cancer Cells

NEW YORK, June 3, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that three abstracts highlighting data and findings from the Company's pivotal Phase 3 SIERRA trial for lead program Iomab-B, have been accepted for 2 oral and 2 poster presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting, which is being held virtually June 11 – 14, 2021. Coinciding with SNMMI, Actinium will be hosting two Iomab-B advisory board meetings with nuclear medicine physicians, technicians, pharmacists, and physicists.

Actinium Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Meeting

Aikido Pharma Inc.

Atossa Genetics

Bionano Genomics

CTI BioPharma

Immutep Ltd

Onconova Therapeutics

These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on InvestorPlace.

7 Reddit Penny Stocks Promising to Cure Cancer

NEW YORK, March 31, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Cell & Gene Meeting on the Mediterranean, which is being held virtually April 6 – 9, 2021, where it will feature its Iomab-ACT program. Iomab-ACT is an extension of Actinium's lead program, Iomab-B, which is being studied in a pivotal Phase 3 trial for targeted myeloablative conditioning prior to a bone marrow transplant.

Actinium to Participate in the Cell & Gene Meeting on the Mediterranean

NEW YORK, March 25, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that initial patient enrollment in the second dose cohort in the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in fit and unfit patients with relapsed or refractory Acute Myeloid Leukemia (r/r AML) has been completed. The Phase 1 portion of the trial is a 3 + 3 dose escalation study to determine the maximum tolerable dose of Actimab-A that is to be studied in the Phase 2 portion of the study.

Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AML

INDIANAPOLIS--(BUSINESS WIRE)--Anthem, Inc. (NYSE: ATNM) today announced that the company has entered into an agreement to acquire myNEXUS, Inc. (“myNEXUS”), a comprehensive home-based nursing management company for payors. myNEXUS delivers integrated clinical support services for approximately 1.7 million Medicare Advantage members across 20 states. “Providing timely care for members in their homes allows for both excellent personalized care as well as the comfort of being in preferred environ

Anthem, Inc. To Acquire myNEXUS, Home Health Benefits Manager

NEW YORK, March 24, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its collaborator, Memorial Sloan Kettering Cancer Center ("MSK"), has commenced patient enrollment in the Phase 1 study evaluating Iomab-ACT for targeted conditioning prior to treatment with MSK's CD19 targeted CAR T-cell 19-28z. Iomab-ACT is a low dose version of Actinium's Phase 3 drug candidate Iomab-B, a CD45 targeting antibody radiation conjugate ("ARC").

Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy

NEW YORK, March 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that preclinical feasibility data supporting an Actinium-225-based CD45-targeted Next-Generation conditioning agent has been accepted for poster presentation at the American Association of Cancer Research (AACR 2021) annual meeting being held virtually April 10 th – 15th, 2021. The data to be presented includes initial dose escalation, safety, tolerability, and conditioning experiments of an Ac-225-based CD45 ARC or antibody radiation conjugate.

Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC

NEW YORK, March 2, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that management will participate in the H.C. Wainwright (HCW) Global Life Sciences Conference, which is being held digitally March 9-10, 2021. Members of Actinium's...

Actinium Announces Participation in H.C. Wainwright Global Life Sciences Conference

NEW YORK, Feb. 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its presence at the 2021 Transplantation & Cellular Therapy (TCT) Annual Meeting, which is being held virtually from February 8th – 12th. The TCT...

Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting

NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that management will participate in the BIO CEO & Investor conference, which is being held digitally February 16 – 18, 2021. Members of Actinium's...

Actinium Announces Participation in BIO CEO & Investor Digital Conference

NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that members of its executive team will participate in a fireside chat at the B. Riley Oncology Investor Conference, which is being held virtually from January 20th to...

Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference

NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas") to develop novel targeted radiotherapies using its Antibody Warhead Enabling (AWE)...

News for Actinium Pharmaceuticals Stock (ATNM)